MeiraGTx Plc(NASDAQ) MGTX

MeiraGTx Holdings plc makes medicines to treat blindness and Parkinson's disease. These genetic therapies help people with serious or rare illnesses. The company builds its own tools to deliver these treatments.

Engineering the Code of Life

• Ocular Therapies: Medicines for inherited forms of blindness; includes treatments for rare diseases that cause progressive vision loss.
• Xerostomia Treatments: Programs for radiation-induced dry mouth in cancer patients; uses genetic material to help restore salivary gland function.
• Neurodegenerative Programs: Investigational treatments for Parkinson’s disease and other disorders affecting the brain and nervous system.
• Riboswitch Platform: Technology allowing precise control of genetic medicine dosage using an oral pill instead of injections.
• Manufacturing Services: Production of viral vectors, which are tools used to carry genetic material into cells for pharmaceutical partners.

Big Partners and New Paths

• Reacquired full rights to the bota-vec eye disease program from Janssen Pharmaceuticals on April 15, 2026.
• Formed a strategic collaboration with Hologen on March 9, 2025, to develop central nervous system therapies.
• Entered a global licensing agreement with Eli Lilly and Company on Nov. 7, 2025, for eye disease research.
• Secured a strategic investment of up to $400 million from Oberland Capital in June 2026.

Total Control Over the Process

MeiraGTx operates its own licensed manufacturing and quality control facilities in London and Ireland. This vertical integration allows the company to control the entire production process from early research to commercial readiness.

MeiraGTx by the Numbers

• Total revenue was $321.4 million in the three-month period ended June 30, 2026.
• Net income reached $114.4 million during the six-month period ended June 30, 2026.
• Market capitalization grew 135.1% year over year to $1.2 billion in Q2 2026.
• Cash and cash equivalents totaled $145.4 million as of June 30, 2026.

The Path Ahead

MeiraGTx has evolved from a research firm into a clinical-stage company with its own manufacturing and high-value drug programs. Its ability to secure major partnerships while reacquiring key assets supports its growth in the genetic medicine market.